Regeneron's high-dose Eylea shows staying power as company awaits FDA decision

As Regeneron anxiously awaits an FDA decision on a high-dose version of Eylea (aflibercept), the company has continually referred to its durability compared to that of Roche’s upstart Vabysmos—which has taken the macular degeneration (AMD) market by storm since receiving approval 19 months ago.